April 11, 2017
Sumitomo Dainippon Pharma said on April 7 that it will grant exclusive development and commercialization rights for its atypical antipsychotic lurasidone in South Korea for local partner Bukwang Pharmaceutical. Under the deal, Bukwang will carry out the bridging PIII study...read more